Alzinova
0.59 SEK
-0.84 %
Less than 1K followers
ALZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Alzinova
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 6.8 | 14.9 | 0.3 | ||||
| growth-% | 118.8 % | ||||||
| EBITDA | -6.2 | -6.5 | -7.5 | -13.1 | -16.5 | -20.4 | - |
| EBIT | -6.2 | -6.5 | -7.5 | -13.1 | -16.5 | -20.4 | -25.6 |
| Profit before taxes | -6.2 | -6.5 | -7.6 | -13.1 | -16.5 | -20.6 | -26.3 |
| Net income | -6.2 | -6.5 | -7.6 | -13.1 | -16.5 | -20.6 | -26.3 |
| EPS | -0.45 | -0.30 | -0.35 | -0.32 | -0.33 | -0.31 | -0.27 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -90.7 % | -43.6 % | -6,118.5 % | ||||
| EBIT-% | -90.7 % | -43.6 % | -6,118.5 % | ||||
| ROE | -10.5 % | -6.8 % | -8.5 % | -12.4 % | -14.5 % | -16.6 % | -21.5 % |
| ROI | -9.7 % | -6.4 % | -8.2 % | -11.7 % | -13.4 % | -15.4 % | -18.3 % |